The Halberd Corporation inaugurates its wholly-owned subsidiary “Halberd Cancer Therapeutics, LTD”

The Halberd Corporation inaugurates its wholly-owned subsidiary "Halberd Cancer Therapeutics, LTD"

Jackson Center, Pennsylvania, 20 July 2022 – The formation of Halberd (OTC-PINK: HALB”).  Cancer Therapeutics, LTD as a wholly-owned subsidiary was announced by Halberd Corporation (OTC-PINK: “HALB”). The extracorporeal technology patented by Halberd (OTC-PINK:HALB) has demonstrated the capacity to be successfully applied to a wide range of diseases and health-related conditions. For the time being, the new entity will be staffed by Halberd (OTC-PINK:HALB) employees until business opportunities present themselves and suitably qualified individuals are recruited to advance the subsidiary’s mission to develop treatments for various types of cancer. The current staff of Halberd Corporation (OTC-PINK:HALB) is capable of performing any function. The initial sharing of technological achievements will benefit both Halberd Corporation (OTC-PINK:HALB) and Halberd (OTC-PINK:HALB).  Cancer Therapeutics, LTD with this strategy.

William A. Hartman, Chairman, President, and Chief Executive Officer of Halberd Corporation (OTC-PINK:HALB), stated, “We believe the formation of this subsidiary is a concrete way to advance extracorporeal cancer treatment technology. Halberd (OTC-PINK:HALB) has already initiated the creation of cancer-specific antibodies, which will play a crucial role in near-term research. Halberd (OTC-PINK:HALB) anticipates that Halberd (OTC-PINK:HALB) Cancer Therapeutics, LTD could be spun off as a dividend to Halberd (OTC-PINK:HALB) stockholders in the future. We anticipate the formation of additional subsidiaries aligned with specific disease applications/treatments as business opportunities and healthcare demands arise.

About the Halberd Company. (OTC-PINK:HALB).

The Halberd Corporation (OTC-PINK:HALB) is an OTC Market public company that complies with all OTC Market reporting requirements. Since its reorganization in April 2020, Halberd (OTC-PINK:HALB).  has obtained worldwide exclusive rights to three issued patents and filed 21 related provisional, PCT, or utility patent applications to increase its stockholder value and attract potential development partners.

Featured Image: Megapixl @lightsource